Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III. The primary endpoint was the proportion of patients maintaining hematocrit below 45% without requiring phlebotomy during weeks 18 through 36. Romano said 88% of patients receiving divesiran across the combined active-treatment arms met the response criteria, compared with 18% of patients receiving placebo. Safety Profile and Phase III PlanningRomano said divesiran was generally well tolerated, with no new safety issues identified. About Silence Therapeutics (NASDAQ:SLN)Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics.